Plasma Neurofilament Light Chain Is Elevated after Transcatheter Aortic Valve Implantation

Cardiology. 2023;148(5):478-484. doi: 10.1159/000532041. Epub 2023 Jul 28.

Abstract

Introduction: Transcatheter aortic valve implantation (TAVI) is associated with a high incidence of new silent brain infarcts (SBIs) on postprocedural neuroimaging. A venous blood sample reflecting neuronal damage following TAVI could help identify patients with potential SBIs. We aimed to investigate if a biochemical marker of neuronal injury, neurofilament light chain (NFL), is elevated after TAVI.

Methods: In this observational study, NFL was measured in plasma from 31 patients before and after TAVI. Multivariable regression analysis was performed to investigate any effect of clinical- and procedure-related factors on differences in NFL levels before and after TAVI.

Results: Samples were collected 41 (14-81) days before and 44 (35-59) days after TAVI, median (interquartile range). Median age was 81 (77-84) years, and 35% were female. No patient had any overt procedure-related neurological complications. The geometric mean (95% confidence interval) of the NFL concentration was 30 (25-36) pg/mL before TAVI and 48 (39-61) pg/mL, after TAVI, p <0.001. None of the included variables in the multiple linear regression model were statistically significantly associated with the difference in levels before and after TAVI.

Conclusions: NFL levels in plasma were higher after TAVI as compared with levels before, with a mean increase of 60% (18 pg/mL). Further studies including neuroimaging and cognitive outcomes are needed to understand the potential value of measuring NFL in relation to TAVI.

Keywords: Biochemical markers; Clinical research; Neurofilament; Silent brain infarcts; Transcatheter aortic valve implantation.

Publication types

  • Observational Study

MeSH terms

  • Aged, 80 and over
  • Aortic Valve Stenosis* / surgery
  • Brain Infarction* / blood
  • Brain Infarction* / etiology
  • Female
  • Humans
  • Male
  • Neurofilament Proteins* / blood
  • Risk Factors
  • Transcatheter Aortic Valve Replacement* / adverse effects
  • Treatment Outcome

Substances

  • neurofilament protein L
  • Neurofilament Proteins